| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neglected Diseases | 6 | 2021 | 381 | 1.87 | Why? |
| Bolivia | 12 | 2021 | 187 | 1.03 | Why? |
| Hand, Foot and Mouth Disease | 2 | 2019 | 115 | 0.79 | Why? |
| Strongyloidiasis | 2 | 2017 | 80 | 0.78 | Why? |
| Child, Adopted | 1 | 2018 | 15 | 0.77 | Why? |
| Mebendazole | 1 | 2018 | 6 | 0.76 | Why? |
| Rural Population | 8 | 2021 | 2408 | 0.75 | Why? |
| Immunoblotting | 1 | 2018 | 180 | 0.72 | Why? |
| Anthelmintics | 2 | 2018 | 104 | 0.72 | Why? |
| Prescription Drug Misuse | 1 | 2018 | 54 | 0.71 | Why? |
| Neurocysticercosis | 1 | 2018 | 51 | 0.70 | Why? |
| Intestinal Diseases, Parasitic | 1 | 2017 | 34 | 0.69 | Why? |
| Trypanosoma cruzi | 1 | 2018 | 133 | 0.69 | Why? |
| Hepatitis A virus | 1 | 2018 | 68 | 0.69 | Why? |
| Helminthiasis | 1 | 2018 | 78 | 0.67 | Why? |
| Measles | 2 | 2018 | 608 | 0.66 | Why? |
| Enterovirus | 2 | 2019 | 402 | 0.66 | Why? |
| Strongyloides stercoralis | 1 | 2017 | 70 | 0.65 | Why? |
| Malaria, Falciparum | 2 | 2018 | 377 | 0.65 | Why? |
| Chagas Disease | 1 | 2018 | 155 | 0.64 | Why? |
| Tuberculin Test | 1 | 2017 | 141 | 0.62 | Why? |
| Tropical Medicine | 2 | 2021 | 237 | 0.58 | Why? |
| Plasmodium falciparum | 1 | 2018 | 337 | 0.57 | Why? |
| Helicobacter pylori | 1 | 2018 | 262 | 0.56 | Why? |
| Interferon-gamma Release Tests | 1 | 2017 | 253 | 0.55 | Why? |
| Taenia solium | 3 | 2018 | 26 | 0.55 | Why? |
| Hepatitis E virus | 1 | 2018 | 306 | 0.54 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.53 | Why? |
| Emigrants and Immigrants | 3 | 2019 | 888 | 0.53 | Why? |
| Antitubercular Agents | 2 | 2017 | 775 | 0.51 | Why? |
| Dog Diseases | 1 | 2018 | 745 | 0.46 | Why? |
| Italy | 28 | 2021 | 38444 | 0.42 | Why? |
| Seroepidemiologic Studies | 5 | 2018 | 10017 | 0.38 | Why? |
| Antibodies, Helminth | 2 | 2018 | 48 | 0.37 | Why? |
| Schistosomiasis haematobia | 2 | 2019 | 45 | 0.36 | Why? |
| Cysticercosis | 2 | 2018 | 32 | 0.34 | Why? |
| Soil | 2 | 2018 | 137 | 0.33 | Why? |
| Tuberculosis | 3 | 2018 | 2895 | 0.32 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.32 | Why? |
| Meningitis, Meningococcal | 2 | 2018 | 114 | 0.32 | Why? |
| Enterobacteriaceae | 2 | 2019 | 395 | 0.28 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.27 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.26 | Why? |
| Hand Hygiene | 1 | 2014 | 1493 | 0.25 | Why? |
| Schistosoma haematobium | 2 | 2019 | 35 | 0.24 | Why? |
| Klebsiella Infections | 2 | 2017 | 466 | 0.23 | Why? |
| Dengue | 3 | 2020 | 1565 | 0.22 | Why? |
| beta-Lactamases | 2 | 2019 | 759 | 0.22 | Why? |
| Guideline Adherence | 1 | 2014 | 2309 | 0.21 | Why? |
| Schistosoma japonicum | 1 | 2019 | 7 | 0.21 | Why? |
| Leadership | 1 | 2014 | 2241 | 0.20 | Why? |
| Travel | 3 | 2017 | 7220 | 0.20 | Why? |
| Male | 49 | 2021 | 367725 | 0.20 | Why? |
| Transients and Migrants | 4 | 2019 | 1468 | 0.20 | Why? |
| Female | 46 | 2021 | 380317 | 0.19 | Why? |
| Splenic Diseases | 1 | 2019 | 28 | 0.19 | Why? |
| Sodium | 1 | 2021 | 309 | 0.19 | Why? |
| Antigens, Helminth | 1 | 2018 | 54 | 0.19 | Why? |
| Mycobacterium tuberculosis | 2 | 2018 | 1164 | 0.19 | Why? |
| Semen | 2 | 2021 | 550 | 0.19 | Why? |
| Cytotoxicity, Immunologic | 1 | 2020 | 287 | 0.18 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.18 | Why? |
| Meningococcal Infections | 2 | 2018 | 216 | 0.18 | Why? |
| Janus Kinase 1 | 1 | 2020 | 254 | 0.18 | Why? |
| Janus Kinase 2 | 1 | 2020 | 218 | 0.18 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.18 | Why? |
| Citrobacter | 1 | 2017 | 5 | 0.18 | Why? |
| Diagnosis, Differential | 7 | 2020 | 7220 | 0.18 | Why? |
| Leishmaniasis, Visceral | 1 | 2019 | 85 | 0.18 | Why? |
| Colistin | 2 | 2017 | 217 | 0.18 | Why? |
| Adult | 36 | 2021 | 244371 | 0.17 | Why? |
| Humans | 71 | 2021 | 930598 | 0.17 | Why? |
| Antibiotics, Antitubercular | 1 | 2017 | 65 | 0.17 | Why? |
| beta-Lactam Resistance | 1 | 2019 | 150 | 0.17 | Why? |
| Carbapenems | 2 | 2018 | 343 | 0.17 | Why? |
| Carrier State | 2 | 2020 | 2100 | 0.17 | Why? |
| Filariasis | 1 | 1997 | 18 | 0.17 | Why? |
| Tacrolimus | 1 | 2020 | 435 | 0.17 | Why? |
| Refugees | 2 | 2017 | 809 | 0.17 | Why? |
| Thienamycins | 1 | 2017 | 72 | 0.17 | Why? |
| Enterococcus faecalis | 1 | 2017 | 126 | 0.17 | Why? |
| Epilepsy | 2 | 2021 | 1401 | 0.17 | Why? |
| Echinococcosis | 1 | 2017 | 40 | 0.16 | Why? |
| Pulmonary Eosinophilia | 1 | 1997 | 46 | 0.16 | Why? |
| Endothelial Progenitor Cells | 1 | 2018 | 103 | 0.16 | Why? |
| Animals, Domestic | 1 | 2018 | 272 | 0.16 | Why? |
| Morocco | 1 | 2018 | 449 | 0.16 | Why? |
| Transplantation, Autologous | 1 | 2018 | 364 | 0.16 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.16 | Why? |
| Linezolid | 1 | 2017 | 160 | 0.16 | Why? |
| Myeloproliferative Disorders | 1 | 2021 | 507 | 0.16 | Why? |
| Food Microbiology | 1 | 2017 | 114 | 0.16 | Why? |
| Drug Therapy | 1 | 2019 | 280 | 0.16 | Why? |
| Artemisinins | 1 | 2018 | 238 | 0.16 | Why? |
| Joint Diseases | 1 | 2017 | 122 | 0.16 | Why? |
| Interleukin-2 | 1 | 2018 | 443 | 0.16 | Why? |
| Soccer | 1 | 2020 | 259 | 0.16 | Why? |
| Schistosomiasis | 1 | 2017 | 59 | 0.15 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.15 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.15 | Why? |
| Parasitic Diseases | 1 | 2017 | 84 | 0.15 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.15 | Why? |
| Herpesvirus 3, Human | 1 | 2018 | 228 | 0.15 | Why? |
| Clinical Deterioration | 1 | 2020 | 473 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Interleukin-6 | 4 | 2021 | 7522 | 0.15 | Why? |
| Myeloid Cells | 1 | 2020 | 808 | 0.15 | Why? |
| Antimalarials | 2 | 2018 | 2505 | 0.15 | Why? |
| Adolescent | 16 | 2021 | 86841 | 0.14 | Why? |
| Neisseria meningitidis | 1 | 2017 | 229 | 0.14 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.14 | Why? |
| Young Adult | 19 | 2021 | 93724 | 0.14 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.14 | Why? |
| Chickenpox | 1 | 2018 | 194 | 0.14 | Why? |
| Bone Marrow Transplantation | 1 | 2018 | 343 | 0.14 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.14 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.14 | Why? |
| Spleen | 1 | 2019 | 877 | 0.14 | Why? |
| Antiparasitic Agents | 1 | 2017 | 267 | 0.14 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.14 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.14 | Why? |
| Drug Resistance, Bacterial | 3 | 2018 | 1414 | 0.14 | Why? |
| Quinolines | 1 | 2018 | 403 | 0.14 | Why? |
| Latent Tuberculosis | 1 | 2018 | 324 | 0.13 | Why? |
| Lipids | 1 | 2021 | 1079 | 0.13 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2017 | 323 | 0.13 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.13 | Why? |
| Pyrazoles | 2 | 2021 | 1791 | 0.13 | Why? |
| Prosthesis-Related Infections | 1 | 2017 | 302 | 0.13 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.13 | Why? |
| Chikungunya virus | 1 | 2017 | 339 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.13 | Why? |
| Immune Sera | 1 | 2018 | 884 | 0.13 | Why? |
| Scleroderma, Systemic | 1 | 2020 | 583 | 0.13 | Why? |
| Dengue Virus | 2 | 2020 | 910 | 0.13 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.13 | Why? |
| Enterobacteriaceae Infections | 1 | 2019 | 529 | 0.12 | Why? |
| Indonesia | 1 | 2017 | 1022 | 0.12 | Why? |
| Child | 10 | 2021 | 70012 | 0.12 | Why? |
| Rhabdomyolysis | 1 | 2017 | 287 | 0.12 | Why? |
| Chikungunya Fever | 1 | 2017 | 345 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Aged | 27 | 2021 | 215776 | 0.12 | Why? |
| Acinetobacter baumannii | 1 | 2015 | 378 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.11 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.11 | Why? |
| Dogs | 1 | 2018 | 2529 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Retrospective Studies | 15 | 2021 | 105322 | 0.11 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.11 | Why? |
| Hepatitis B virus | 1 | 2018 | 882 | 0.11 | Why? |
| Photophobia | 1 | 2010 | 14 | 0.11 | Why? |
| Parapsoriasis | 1 | 2010 | 12 | 0.11 | Why? |
| General Practitioners | 1 | 2018 | 568 | 0.11 | Why? |
| Depsipeptides | 1 | 1990 | 61 | 0.10 | Why? |
| Whole Genome Sequencing | 2 | 2018 | 3239 | 0.10 | Why? |
| Treatment Outcome | 9 | 2020 | 51732 | 0.10 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.10 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.10 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.10 | Why? |
| Infant | 6 | 2019 | 30274 | 0.10 | Why? |
| Ischemia | 1 | 2018 | 901 | 0.10 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.10 | Why? |
| Animals | 9 | 2019 | 78931 | 0.10 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.10 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.10 | Why? |
| Gram-Positive Bacteria | 1 | 1990 | 230 | 0.10 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.09 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.09 | Why? |
| Prevalence | 4 | 2019 | 25773 | 0.09 | Why? |
| Africa South of the Sahara | 3 | 2019 | 1335 | 0.09 | Why? |
| Child, Preschool | 6 | 2018 | 36283 | 0.09 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.09 | Why? |
| Peptides, Cyclic | 1 | 1990 | 223 | 0.09 | Why? |
| Tuberculosis, Pulmonary | 1 | 2019 | 1171 | 0.09 | Why? |
| Thrombophilia | 1 | 2021 | 1935 | 0.09 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.09 | Why? |
| Contact Tracing | 3 | 2020 | 8448 | 0.09 | Why? |
| Mass Vaccination | 1 | 2018 | 1101 | 0.09 | Why? |
| Seizures | 1 | 2017 | 1163 | 0.09 | Why? |
| Adjuvants, Immunologic | 1 | 2017 | 1709 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2020 | 9091 | 0.08 | Why? |
| Aged, 80 and over | 11 | 2021 | 88759 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.08 | Why? |
| Survival Analysis | 4 | 2021 | 7592 | 0.08 | Why? |
| Nitriles | 2 | 2021 | 1053 | 0.08 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Immunocompromised Host | 2 | 2020 | 5150 | 0.07 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.07 | Why? |
| Critical Care | 4 | 2021 | 14081 | 0.07 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2018 | 1115 | 0.07 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.07 | Why? |
| Coronavirus | 3 | 2020 | 18339 | 0.07 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.07 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.07 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.07 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.07 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| Pyrimidines | 2 | 2021 | 1557 | 0.06 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.06 | Why? |
| Immunoglobulin G | 4 | 2020 | 21571 | 0.06 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 533 | 0.06 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.06 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.06 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.06 | Why? |
| Hydrocarbons, Brominated | 1 | 2021 | 21 | 0.06 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.06 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.06 | Why? |
| Optic Atrophies, Hereditary | 1 | 2020 | 14 | 0.06 | Why? |
| Leber Congenital Amaurosis | 1 | 2020 | 15 | 0.06 | Why? |
| Ciliopathies | 1 | 2020 | 16 | 0.06 | Why? |
| Klebsiella pneumoniae | 2 | 2017 | 658 | 0.06 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Kidney Diseases, Cystic | 1 | 2020 | 30 | 0.05 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.05 | Why? |
| Schistosomiasis japonica | 1 | 2019 | 3 | 0.05 | Why? |
| Fluorocarbons | 1 | 2021 | 102 | 0.05 | Why? |
| Personnel, Hospital | 1 | 2014 | 2273 | 0.05 | Why? |
| Semen Analysis | 1 | 2021 | 235 | 0.05 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.05 | Why? |
| Hypernatremia | 1 | 2021 | 182 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Methylprednisolone | 2 | 2021 | 2107 | 0.05 | Why? |
| C-Reactive Protein | 3 | 2020 | 7972 | 0.05 | Why? |
| Cobicistat | 1 | 2020 | 172 | 0.05 | Why? |
| Respiratory Care Units | 1 | 2020 | 111 | 0.05 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.05 | Why? |
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2021 | 277 | 0.05 | Why? |
| Neisseria meningitidis, Serogroup C | 1 | 2018 | 46 | 0.05 | Why? |
| Deprescriptions | 1 | 2020 | 294 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Medical History Taking | 1 | 2020 | 350 | 0.05 | Why? |
| Fever | 2 | 2017 | 7795 | 0.04 | Why? |
| Escherichia coli Proteins | 1 | 2018 | 168 | 0.04 | Why? |
| Pandemics | 11 | 2021 | 389249 | 0.04 | Why? |
| Diethylcarbamazine | 1 | 1997 | 11 | 0.04 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.04 | Why? |
| Hepatitis B Antibodies | 1 | 2018 | 142 | 0.04 | Why? |
| Solanum tuberosum | 1 | 2017 | 27 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Travel Medicine | 1 | 2021 | 335 | 0.04 | Why? |
| Filaricides | 1 | 1997 | 41 | 0.04 | Why? |
| Spirometry | 1 | 2020 | 524 | 0.04 | Why? |
| Bone Marrow Cells | 1 | 2018 | 186 | 0.04 | Why? |
| Philippines | 1 | 2019 | 568 | 0.04 | Why? |
| ROC Curve | 2 | 2020 | 6024 | 0.04 | Why? |
| Extremities | 1 | 2018 | 179 | 0.04 | Why? |
| Hyponatremia | 1 | 2021 | 371 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.04 | Why? |
| Receptors, Immunologic | 1 | 2020 | 555 | 0.04 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Africa, Western | 1 | 2017 | 363 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Europe | 3 | 2017 | 12702 | 0.04 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.04 | Why? |
| Amputation | 1 | 2018 | 331 | 0.04 | Why? |
| Microbial Sensitivity Tests | 2 | 2017 | 2886 | 0.04 | Why? |
| Creatine Kinase | 1 | 2017 | 386 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| South America | 1 | 2017 | 565 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.04 | Why? |
| Developing Countries | 2 | 2021 | 4283 | 0.04 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.04 | Why? |
| Escherichia coli Infections | 1 | 2018 | 348 | 0.04 | Why? |
| Hypoxia | 1 | 2010 | 3626 | 0.04 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.04 | Why? |
| Drug Therapy, Combination | 3 | 2017 | 7268 | 0.04 | Why? |
| Allografts | 1 | 2018 | 761 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Cannula | 1 | 2020 | 750 | 0.03 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.03 | Why? |
| Common Cold | 1 | 2020 | 645 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2017 | 446 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Species Specificity | 1 | 2018 | 1356 | 0.03 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Interleukin-10 | 1 | 2020 | 1409 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.03 | Why? |
| Patient Transfer | 1 | 2020 | 898 | 0.03 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.03 | Why? |
| Emigration and Immigration | 1 | 2018 | 501 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Acinetobacter Infections | 1 | 2015 | 273 | 0.03 | Why? |
| Athletes | 1 | 2020 | 1047 | 0.03 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2017 | 363 | 0.03 | Why? |
| Analgesia | 1 | 1995 | 211 | 0.03 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.03 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.03 | Why? |
| Ristocetin | 1 | 1990 | 4 | 0.03 | Why? |
| Cross Infection | 1 | 2014 | 8675 | 0.03 | Why? |
| Latin America | 1 | 2017 | 1721 | 0.03 | Why? |
| Rifamycins | 1 | 1990 | 20 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Frail Elderly | 1 | 2021 | 1427 | 0.03 | Why? |
| Pain, Postoperative | 1 | 1995 | 289 | 0.03 | Why? |
| Methicillin Resistance | 1 | 1990 | 77 | 0.03 | Why? |
| Streptococcus | 1 | 1990 | 76 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Jordan | 1 | 2013 | 701 | 0.03 | Why? |
| Staphylococcus | 1 | 1990 | 77 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.03 | Why? |
| Daptomycin | 1 | 1990 | 64 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Nigeria | 1 | 2017 | 2292 | 0.02 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2020 | 1881 | 0.02 | Why? |
| Fatigue | 1 | 2020 | 2479 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| L-Lactate Dehydrogenase | 1 | 2017 | 1995 | 0.02 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Teicoplanin | 1 | 1990 | 191 | 0.02 | Why? |
| Glycopeptides | 1 | 1990 | 199 | 0.02 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.02 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.02 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Syndrome | 1 | 2013 | 1310 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Vancomycin | 1 | 1990 | 328 | 0.02 | Why? |
| Infant, Newborn | 2 | 2019 | 23105 | 0.02 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Drug Resistance, Microbial | 1 | 1990 | 419 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.02 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Kidney Failure, Chronic | 1 | 2020 | 3222 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| HIV Antibodies | 1 | 1989 | 776 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Public Health | 2 | 2017 | 16359 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Peptides | 1 | 1990 | 2513 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.01 | Why? |
| SARS Virus | 1 | 2021 | 13021 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Excitatory Amino Acids | 1 | 1995 | 1 | 0.01 | Why? |
| Nociceptors | 1 | 1995 | 33 | 0.01 | Why? |
| Neuropeptides | 1 | 1995 | 91 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 11367 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| China | 1 | 2019 | 50654 | 0.01 | Why? |
| Anesthetics, Local | 1 | 1995 | 205 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Analgesics, Opioid | 1 | 1995 | 1070 | 0.00 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 1454 | 0.00 | Why? |
| Research | 1 | 1995 | 2115 | 0.00 | Why? |
| Clinical Trials as Topic | 1 | 1995 | 7330 | 0.00 | Why? |